Sep 25, 2026 07:00AM
Sep 25, 2026 07:00AM
Sep 16, 2026 07:00AM
Sep 9, 2026 07:01AM
Sep 9, 2026 07:00AM
Aug 14, 2026 07:00AM
Aug 14, 2026 07:00AM Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Aug 13, 2026 08:30AM
Jul 10, 2026 06:52AM
Jul 9, 2026 08:30AM
Jul 9, 2026 08:30AM
Jul 6, 2026 08:31AM
Jul 6, 2026 08:30AM
Jun 12, 2026 08:10AM After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
Jun 4, 2026 08:32AM
Jun 4, 2026 08:30AM
Jun 1, 2026 08:30AM
May 21, 2026 08:32AM
May 21, 2026 08:30AM
May 13, 2026 08:30AM
May 11, 2026 08:31AM Fate Therapeutics reports clinical progress for FT819 lupus treatment
May 11, 2026 08:30AM
May 5, 2026 08:31AM
May 5, 2026 08:30AM
May 4, 2026 09:00AM
Apr 30, 2026 09:00AM
Mar 18, 2026 11:30AM
Feb 26, 2026 09:00AM Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Jan 23, 2026 12:56PM
Dec 21, 2025 04:00AM
Dec 8, 2025 08:00AM
Dec 8, 2025 08:00AM
Oct 27, 2025 12:29AM
Oct 26, 2025 11:30AM
Sep 3, 2025 06:20AM Fate Therapeutics (FATE) PT Lowered to $7 at Leerink Partners
Aug 12, 2025 04:01PM
Jun 11, 2025 01:00PM
Jun 11, 2025 09:02AM
Jun 11, 2025 09:00AM
May 13, 2025 04:01PM
Apr 14, 2025 08:01AM
Apr 14, 2025 08:00AM Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
Mar 6, 2025 05:19AM
Mar 5, 2025 04:01PM
Jan 2, 2025 04:00PM
Nov 12, 2024 04:01PM
Aug 13, 2024 04:05PM
May 9, 2024 04:01PM
May 9, 2024 08:38AM Fate Therapeutics (FATE) Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
May 9, 2024 08:30AM

332,308 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All